Study investigated IL-6 and ferritin levels as biomarkers in DLBCL patients receiving CAR-T therapy.
Home / Resource Library / Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients